Kura Oncology, Inc. (FRA:KUR)

Germany flag Germany · Delayed Price · Currency is EUR
10.07
-0.27 (-2.56%)
Last updated: Dec 1, 2025, 8:19 AM CET
-3.45%
Market Cap911.03M
Revenue (ttm)88.66M
Net Income (ttm)-184.85M
Shares Outn/a
EPS (ttm)-2.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume198
Open10.07
Previous Close10.34
Day's Range10.07 - 10.07
52-Week Range4.68 - 10.78
Betan/a
RSI58.61
Earnings DateFeb 26, 2026

About Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for ... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Troy Wilson
Employees 192
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol KUR
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.